Skip to main content
. 2021 Oct 5;12(10):908. doi: 10.1038/s41419-021-04209-2

Fig. 6. In vivo animal models confirm the ability of miR-342-5p to inhibit CML and enhance the effects of imatinib.

Fig. 6

A Flow diagram of MTAM-system based CML xenograft model. B Representative illustration of subcutaneous implantation of MTAM with K562 CML cells in sacrificed mice. C Results of MTT assay under a paired analysis of K562 expressing miR-NEG or miR-342-5p. Statistical method: two-tailed Paired t-test; ns: not significant difference; *P < 0.05. D One-way ANOVA analysis of the results of MTT assay on imatinib treatment with K562 expressing miR-NEG or miR-342-5p; n = 6 in each group, ns: not significant difference; *P < 0.05; **P < 0.01; ***P < 0.001. Data were in the form of mean ± SD.